Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency [PDF]
, 2009 In mammals, increased GABA in the central nervous system has been associated with abnormalities of visual evoked potentials (VEPs), predominantly manifested as increased latency of the major positive component P100.
Blasi, P +7 more
core +1 more source
Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms
Journal of Central Nervous System Disease, 2011 In 2009, vigabatrin became the first FDA approved medication for the treatment of infantile spasms in the United States. There are few well-designed prospective studies comparing the drug to placebo or other modalities used in the treatment of infantile ...
Michele A. Faulkner, Justin A. Tolman
doaj +1 more source
Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin? [PDF]
, 2014 Purpose Vigabatrin (VGB) is an anti-epileptic medication which has been linked to peripheral constriction of the visual field. Documenting the natural history associated with continued VGB exposure is important when making decisions about the risk and
Conway, M. L. +3 more
core +3 more sources
Neurobiology of Disease, 2004 Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndrome. Following reports of visual field loss associated with vigabatrin therapy, some authors have investigated retinal electrophysiologic variables to ...
Pasquale Parisi +3 more
doaj +1 more source
Treatments for spasticity and pain in multiple sclerosis: a systematic review [PDF]
, 2003 Objectives: To identify the drug treatments currently available for the management of spasticity and pain in multiple sclerosis (MS), and to evaluate their clinical and cost-effectiveness.
Beard, S.M., Hunn, A., Wight, J.
core +1 more source
Vigabatrin-Induced Visual Field Defects
Pediatric Neurology Briefs, 1998 A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 cases of symptomatic visual field defects associated with vigabatrin (usually as add-on therapy) between 1990 and 1997.
J Gordon Millichap
doaj +1 more source
Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. [PDF]
, 2018 There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as type 1 diabetes and rheumatoid arthritis in mouse models.
Dang, Hoa +4 more
core +3 more sources
Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. [PDF]
, 2011 Two years after the warning issued by the Food and Drug Administration on an increased risk of suicide for people taking antiepileptic drugs (AEDs), a number of pharmacoepidemiologic studies have been published but the scientific community is far from ...
Hesdorffer, DC, Mula, M
core +3 more sources
Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex [PDF]
, 2016 Cognitive development in patients with tuberous sclerosis complex is highly variable. Predictors in the infant years would be valuable to counsel parents and to support development.
Bindels-de Heus, G.C.B. (Karen) +9 more
core +4 more sources
Vigabatrin-Associated Visual Field Defects
Pediatric Neurology Briefs, 2001 The prevalence, risk factors, and long-term outcome of vigabatrin-associated visual field defects were examined in 60 adult patients with partial epilepsy treated with vigabatrin for 7 months to 14 years at the University of Kuopio Hospital, Finland.
J Gordon Millichap
doaj +1 more source